Schisandrin A Alleviates Inflammation and Oxidative Stress in Aβ25-35-Induced Alzheimer's Disease in Vitro Model

Overview

Journal Actas Esp Psiquiatr

Specialty Psychiatry

Date 2024 Oct 15

PMID 39403912

Authors

Siting Jia

Huibo Guan

Shujuan Zhang

Quan Li

Affiliations

Soon will be listed here.

Abstract

Background: Schisandra extract has therapeutic and preventive effects on Alzheimer's disease (AD). Therefore, this study evaluated the anti-AD potential of Schisandrin A (SCH A) using an in vitro cell model.

Methods: SH-SY5Y and SK-N-SH cells were treated with 20 µM amyloid β-protein (Aβ)25-35. The Aβ25-35-induced cells were then exposed to different concentrations of SCH A (1, 5, 10, 15 µg/mL). Moreover, to further explore the role of the extracellular signal-regulated kinase (ERK)/mitogen-activated protein kinase (MAPK) pathway in the anti-AD effects of SHC A, SH-SY5Y cells were treated with SCH A following incubation with ERK activator LM22B-10. The impact of SCH A on cell viability and apoptosis was evaluated using 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide (MTT) and flow cytometry. Furthermore, the oxidative stress markers and inflammatory cytokine levels were also assessed. The reactive oxygen species (ROS) levels were examined using 2',7'-Dichlorodihydrofluorescein Diacetate (DCFH-DA) method. Finally, Western blot analysis was employed to evaluate the phospho-ERK1/2 (p-ERK1/2) and ERK1/2.

Results: We observed that SCH A treatment (5, 10, 15 µg/mL) substantially increased the cell viability (p < 0.05), and reduced the apoptosis rate (10 and 15 µg/mL) in SH-SY5Y and SK-N-SH cells (p < 0.05). SCH A significantly ameliorated oxidative stress and reduced inflammatory cytokine levels in Aβ25-35-induced cells (p < 0.05). Furthermore, SCH A up-regulated the p-ERK1/2 to ERK1/2 ratio in Aβ25-35-induced cells. However, LM22B-10 treatment was found to exacerbate this effect of SCH A (p < 0.05).

Conclusion: SCH A reduces the Aβ25-35-induced inflammatory response and oxidative stress in SH-SY5Y and SK-N-SH cells, and the activation of the ERK/MAPK signaling pathway was related to its potential mechanism.

References

Cai N, Geng Q, Jiang Y, Zhu W, Yang R, Zhang B . Schisandrin A and B affect the proliferation and differentiation of neural stem cells. J Chem Neuroanat. 2021; 119:102058. DOI: 10.1016/j.jchemneu.2021.102058. View

Chu B, Li M, Cao X, Li R, Jin S, Yang H . IRE1α-XBP1 Affects the Mitochondrial Function of Aβ25-35-Treated SH-SY5Y Cells by Regulating Mitochondria-Associated Endoplasmic Reticulum Membranes. Front Cell Neurosci. 2021; 15:614556. PMC: 8027129. DOI: 10.3389/fncel.2021.614556. View

Zong W, Gouda M, Cai E, Wang R, Xu W, Wu Y . The Antioxidant Phytochemical Schisandrin A Promotes Neural Cell Proliferation and Differentiation after Ischemic Brain Injury. Molecules. 2021; 26(24). PMC: 8706049. DOI: 10.3390/molecules26247466. View

Zhang N, Xu H, Wang Y, Yao Y, Liu G, Lei X . Protective mechanism of kaempferol against Aβ-mediated apoptosis of pheochromocytoma (PC-12) cells through the ER/ERK/MAPK signalling pathway. Arch Med Sci. 2021; 17(2):406-416. PMC: 7959041. DOI: 10.5114/aoms.2020.98199. View

Zhang G, Pare R, Chin K, Qian Y . Tβ4 ameliorates oxidative damage and apoptosis through ERK/MAPK and 5-HT1A signaling pathway in Aβ insulted SH-SY5Y cells. Life Sci. 2021; :120178. DOI: 10.1016/j.lfs.2021.120178. View

Atri A . The Alzheimer's Disease Clinical Spectrum: Diagnosis and Management. Med Clin North Am. 2019; 103(2):263-293. DOI: 10.1016/j.mcna.2018.10.009. View

Wang Z, Chen Y, Li X, Sultana P, Yin M, Wang Z . Amyloid-β dynamically regulates the migration of neural stem/progenitor cells via MAPK-ERK pathway. Chem Biol Interact. 2018; 298:96-103. DOI: 10.1016/j.cbi.2018.11.001. View

Liu J, Duan W, Deng Y, Zhang Q, Li R, Long J . New Insights into Molecular Mechanisms Underlying Neurodegenerative Disorders. J Integr Neurosci. 2023; 22(3):58. DOI: 10.31083/j.jin2203058. View

Weller J, Budson A . Current understanding of Alzheimer's disease diagnosis and treatment. F1000Res. 2018; 7. PMC: 6073093. DOI: 10.12688/f1000research.14506.1. View

10.

Nakajima A, Ohizumi Y . Potential Benefits of Nobiletin, A Citrus Flavonoid, against Alzheimer's Disease and Parkinson's Disease. Int J Mol Sci. 2019; 20(14). PMC: 6678479. DOI: 10.3390/ijms20143380. View

11.

Zhao Z, Zhang Y, Zhang Y, Wei X, Wang H, Zhang M . The protective underlying mechanisms of Schisandrin on SH-SY5Y cell model of Alzheimer's disease. J Toxicol Environ Health A. 2019; 82(19):1019-1026. DOI: 10.1080/15287394.2019.1684007. View

12.

Breijyeh Z, Karaman R . Comprehensive Review on Alzheimer's Disease: Causes and Treatment. Molecules. 2020; 25(24). PMC: 7764106. DOI: 10.3390/molecules25245789. View

13.

Ozben T, Ozben S . Neuro-inflammation and anti-inflammatory treatment options for Alzheimer's disease. Clin Biochem. 2019; 72:87-89. DOI: 10.1016/j.clinbiochem.2019.04.001. View

14.

Guo X, Lei M, Ma G, Ouyang C, Yang X, Liu C . Schisandrin A Alleviates Spatial Learning and Memory Impairment in Diabetic Rats by Inhibiting Inflammatory Response and Through Modulation of the PI3K/AKT Pathway. Mol Neurobiol. 2023; 61(5):2514-2529. DOI: 10.1007/s12035-023-03725-w. View

15.

Ma L, Jiang X, Huang Q, Chen W, Zhang H, Pei H . Traditional Chinese medicine for the treatment of Alzheimer's disease: A focus on the microbiota-gut-brain axis. Biomed Pharmacother. 2023; 165:115244. DOI: 10.1016/j.biopha.2023.115244. View

16.

Guo Y, Pan W, Liu S, Shen Z, Xu Y, Hu L . ERK/MAPK signalling pathway and tumorigenesis. Exp Ther Med. 2020; 19(3):1997-2007. PMC: 7027163. DOI: 10.3892/etm.2020.8454. View

17.

Wang X, Li Q, Sui B, Xu M, Pu Z, Qiu T . Schisandrin A from Schisandra chinensis Attenuates Ferroptosis and NLRP3 Inflammasome-Mediated Pyroptosis in Diabetic Nephropathy through Mitochondrial Damage by AdipoR1 Ubiquitination. Oxid Med Cell Longev. 2022; 2022:5411462. PMC: 9391610. DOI: 10.1155/2022/5411462. View

18.

Chen P, Wang R, Liu F, Li S, Gu Y, Wang L . Schizandrin C regulates lipid metabolism and inflammation in liver fibrosis by NF-κB and p38/ERK MAPK signaling pathways. Front Pharmacol. 2023; 14:1092151. PMC: 10242051. DOI: 10.3389/fphar.2023.1092151. View

19.

Ng A, Tam W, Zhang M, Ho C, Husain S, McIntyre R . IL-1β, IL-6, TNF- α and CRP in Elderly Patients with Depression or Alzheimer's disease: Systematic Review and Meta-Analysis. Sci Rep. 2018; 8(1):12050. PMC: 6089986. DOI: 10.1038/s41598-018-30487-6. View